Kasumigaseki Capital Co., Ltd. (3498) Stock Analysis - Comparative Analysis of 4 M&A Candidates in the Hospice Business: Which is the Most Promising?
Please invest at your own risk.
This article is a record of analysis results using ClaudeCode.
Estimated analysis as of April 2026 *Not an investment recommendation
Introduction
In its financial results for the second quarter of the fiscal year ending August 2026, Kasumigaseki Capital (3498) explicitly stated that it is "looking into new business areas and M&A with an eye toward growth beyond the second medium-term management plan."
The current hospice business, "CLASWELL," has grown to 11 facilities, 589 rooms, and a business scale of 45.1 billion yen, but the accumulation of operational know-how, human resources, and the strengthening of a nationwide network are challenges for future expansion.
In this report, we will conduct a multi-faceted comparative analysis of four listed companies related to the hospice market to determine their suitability as M&A candidates for Kasumigaseki Capital.
Current Status of Kasumigaseki Capital's Hospice Business
Brand Name: "CLASWELL"
Opened Facilities: 11 locations, 29.7 billion yen scale
Facilities Under Development: 6 locations, 15.4 billion yen scale
Total: 589 rooms, 45.1 billion yen scale
Position: An "untapped zone" featuring locations near stations, hotel-like designs, and 24-hour nursing care support
Strengths: Land acquisition and facility planning capabilities leveraging Kasumigaseki's real estate development know-how
Challenges: Accumulation of operational know-how, securing nursing staff, and building a nationwide network
Background of the Hospice Market
The annual number of deaths in Japan is expected to reach 1.66 million (4,562 per day) by 2040
The proportion of healthcare facilities as a place of death is increasing rapidly
The number of facilities operated by the three major listed companies (Amvis Holdings, Japan Hospice Holdings, and CUC) has expanded 2.7 times in three years
The government is promoting a shift from "hospitals to home/facilities," and demand for hospice housing is structurally expanding
Overview of 4 M&A Candidate Companies
Candidate 1: Amvis Holdings (Securities Code: 7071)
Market: TSE Prime
Market Capitalization: Approx. 49 billion yen
Revenue: Approx. 49.2 billion yen
Number of Facilities: Over 130 locations ("Ishinkan" brand)
Expansion Area: Nationwide network across 1 metropolis, 1 circuit, 1 prefecture, and 30 prefectures
End-of-Life Care Track Record: Cumulative total of approx. 37,000 people, approx. 11,000 people per year
Candidate 2: CUC Inc. (Securities Code: 9158)
Market: TSE Growth
Market Capitalization: Approx. 70 billion yen
Revenue: Over approx. 50 billion yen (annualized)
Number of Hospice Facilities: Over 50 facilities ("ReHOPE" brand)
Business Structure: Three pillars of hospice, medical institution management support, and home-visit nursing
Overseas Expansion: Developing podiatry business in the United States
Candidate 3: Japan Hospice Holdings Inc. (Securities Code: 7061)
Market: TSE Growth
Market Capitalization: Approx. 20 billion yen
Number of Facilities: Over 40 facilities ("Family Hospice" brand)
Expansion Area: Expanding nationwide, focusing on the Chubu and Kanto regions
Mission: "Research and dissemination of home hospice"
Candidate 4: Sunwels Co., Ltd. (Securities Code: 9229)
Market: TSE Prime (Securities under Supervision)
Market Capitalization: Approx. 8 billion yen (down over 90% from high)
Number of Facilities: 43 facilities ("PD House" brand)
Features: Hospice housing specializing in Parkinson's disease
Status: Certified fraudulent billing, Securities under Supervision, fell into deficit
Detailed Analysis of Each Candidate
1. Amvis Holdings (7071) [Strongest Candidate]
Business Strengths
Largest operating scale in the industry with over 130 locations nationwide under the "Ishinkan" brand
Deep expertise and human resource network accumulated through specialization in end-of-life care
A model that organically combines visiting nursing, home care, and paid nursing homes
Geographical advantage through nationwide expansion covering 1 metropolis, 1 circuit, 1 prefecture, and 30 prefectures
Synergy with Kasumigaseki
Ability to acquire a facility network, human resources, and know-how of 130 locations nationwide at once
High synergy directly linked to Kasumigaseki's "development -> operation -> REIT incorporation" cycle model
Multi-brand development possible with CLASWELL's high price range and Amvis's "Ishinkan" mid-price range
Realization of "complete vertical integration" of real estate development capability and operational capability
M&A Benefits
Immediate acquisition of the industry's largest facility network
Ability to horizontally deploy know-how for 11,000 end-of-life care cases per year to CLASWELL
Largest contribution to AUM among the 4 candidates
M&A Risks and Challenges
High acquisition cost with a market capitalization of 49 billion yen, requiring additional capital procurement
Compliance risks remain due to reports of fraudulent medical billing in March 2025
Recent profit margins are on a downward trend
High PMI difficulty with the 'physician outsourcing' model
Recommended Approach
Start with a 10-20% capital alliance, and increase equity only after confirming the renewal of the compliance system
Gradual stock acquisition taking advantage of stock price declines is realistic
(2) CUC Inc. (9158) [Strong Candidate - Priority on Business Alliance]
Business Strengths
Strong network with hospitals and clinics nationwide through medical institution management support business
Visiting nursing business (nationwide expansion of home care) through subsidiary Sophia Med
Track record of operating over 50 hospices under the 'ReHOPE' brand
High-growth company with continued double-digit revenue growth
Synergy with Kasumigaseki
Medical institution network functions as a pipeline for introducing residents to CLASWELL
Utilize Sophia Med's visiting nursing to enhance care for CLASWELL residents
Enables site selection for high-occupancy facilities through collaboration with medical institutions
Foothold for overseas healthcare real estate investment through international business (USA)
Benefits of M&A
Acquisition of rare assets unavailable to other companies, namely a medical institution network
Ability to build a complete value chain of 'Hospital → Hospice Admission → End-of-Life Care'
Realization of integrated services through consolidation with the home nursing business
M&A Risks and Challenges
Highest acquisition cost among the 4 candidates with a market capitalization of 70 billion yen
Complex PMI involving 3 segments plus overseas operations
Highest goodwill and impairment risk
Additional large-scale financing is essential
Recommended Approach
Start with a business alliance rather than a full acquisition to verify the effectiveness of utilizing the medical institution network
A three-stage approach of capital participation (10-20%) followed by full subsidiary conversion is realistic
③ Japan Hospice Holdings (7061) [Strong Candidate - Ideal for First M&A]
Business Strengths
Purity of brand as a hospice-specialized company and an organizational culture with a strong sense of mission
Continuity of home-to-facility services providing integrated home nursing, home care, and multi-functional long-term care
Strong foundation in the Chubu area (Aichi, Gifu, Shizuoka) and a track record of collaboration with regional medical care
Relatively low initial investment per facility and faster profitability
Synergy with Kasumigaseki
Realization of regional complementarity in the Chubu and Tokyo metropolitan suburban areas where CLASWELL has a weak presence
Acquisition of a hospice-specialized brand will increase the group's hospice recognition
Utilize visiting nursing expertise to enhance CLASWELL's services
Accelerate the construction of large-scale facilities (50-100 room scale) using Kasumigaseki's development capabilities
Benefits of M&A
At approximately 20-24 billion yen, it is the most cost-efficient among the 4 candidates
Can be executed without additional financing within the 42.8 billion yen cash and deposits
The PMI scale is appropriate, making it the optimal first step for accumulating know-how
Allows for the construction of a two-brand system consisting of a hospice-specialized brand and CLASWELL
M&A Risks and Challenges
Limited economies of scale due to the small number of facilities
Growth rate is slightly slower compared to Amvis Holdings and CUC
Additional new development investment is required separately for expansion into the Tokyo metropolitan area
Recommended Approach
Making it a wholly-owned subsidiary via TOB is the most realistic and effective option
Execute as the 'first hospice M&A,' and after accumulating PMI experience, move on to the next large-scale project
④ Sunwels (9229) [Caution: Not recommended at this time]
Business Strengths (Original)
A clear niche position specializing in Parkinson's disease
Infrastructure of 43 'PD House' facilities nationwide
Expertise and specialized know-how in neurological intractable disease care
Current Issues
Over 2.8 billion yen in fraudulent medical fee claims confirmed
Designated as a security under supervision by the TSE Prime Market; risk of delisting exists
Net loss for the current fiscal year projected at approximately -2.2 billion yen
Dysfunction in internal controls and compliance has been pointed out
Greatest risk for Kasumigaseki
Acquiring a company with fraudulent billing issues carries the risk of negatively impacting the brand of the entire group
Trust with institutional investors and financial institutions, which Kasumigaseki focuses on, could be damaged
Room for consideration under conditions
Low-cost acquisition can be considered only after legal and compliance issues are completely resolved
Participation in the form of supporting business reconstruction after the issues are resolved can remain a future option
Acquisition is difficult to recommend at this time
4-Company Comparison: Summary of Evaluation
Immediate Acquisition of Industry Scale and Know-how
Best: Amvis Holdings (130 locations, track record of 11,000 end-of-life care cases annually)
Runner-up: CUC (50 facilities, medical institution network)
3rd Place: Japan Hospice Holdings (40 facilities, depth in hospice specialization)
4th Place: Sunwels (43 facilities but numerous issues)
Acquisition Cost Efficiency
Best: Japan Hospice Holdings (approx. 20-24 billion yen, can be covered by cash and deposits)
Runner-up: Amvis Holdings (approx. 49-60 billion yen; additional funding required)
3rd Place: CUC (approx. 84-91 billion yen; large-scale funding required)
Reference: Sunwels (approx. 8 billion yen; low rating when considering risk issues)
Compatibility with the Kasumigaseki Business Model
Best: Amvis Holdings (complete vertical integration of development, operation, and REIT incorporation)
Runner-up: CUC (synergy between medical network and real estate development)
3rd Place: Japan Hospice Holdings (regional complementarity, hospice-specialized brand)
4th Place: Sunwels (niche specialization is commendable, but there are issues)
Feasibility of PMI (Post-Merger Integration)
Best: Japan Hospice Holdings (appropriate scale, simple hospice-specialized business)
Runner-up: Amvis Holdings (large scale, but simple business)
3rd Place: CUC (integration of diversified businesses is complex)
4th Place: Sunwels (resolution of compliance issues is a prerequisite)
Low Compliance Risk
Best: Japan Hospice Holdings / CUC (no reported issues)
Runner-up: Amvis Holdings (reports of fraudulent billing remain)
4th Place: Sunwels (fraudulent billing confirmed; stock under supervision)
Recommended M&A Strategy: 3-Phase Approach
Phase 1 (Near-term, 2026-2027): Full acquisition of Japan Hospice Holdings (7061)
Total acquisition cost: approx. 24 billion yen (can be covered by cash and deposits)
Objective: Acquisition of hospice operation know-how, expansion into the Chubu area, and accumulation of PMI experience
Effect: Expansion of healthcare AUM from 45.1 billion yen to 60-70 billion yen
Phase 2 (Medium-term, 2027-2028): Business alliance with CUC Inc. (9158) → Capital participation
Capital participation amount: Approximately 7-14 billion yen (acquisition of 10-20%)
Objective: Start utilizing medical institution networks and improve the occupancy rate of CLASWELL
Effect: Establishment of a resident referral pipeline and paving the way for a future full acquisition
Phase 3 (Long-term, 2028-2029): Capital alliance with Amvis Holdings, Inc. (7071) → Full subsidiary acquisition
Total acquisition amount: Approximately 49-60 billion yen (combination of corporate bonds, fund formation, and bank loans)
Objective: Acquire the industry leader's scale, know-how, and nationwide network to establish market dominance
Effect: Expansion of healthcare AUM to over 100 billion yen and a major contribution to the 2029 AUM target of 1.5 trillion yen
Consistency with the 2nd Medium-Term Management Plan
The goals of Kasumigaseki Capital's 2nd Medium-Term Management Plan (2025-2029) are as follows:
Net income: 50 billion yen (fiscal year ending August 2029)
AUM: 1.5 trillion yen scale (fiscal year ending August 2029)
The estimates if the 3-stage M&A strategy is realized are as follows:
Healthcare AUM: Currently 45.1 billion yen → 100-135 billion yen after completion of the 3 stages (+60-90 billion yen)
Contribution to net income: Annual profit increase of +8-12 billion yen after all M&As are completed
Healthcare will become fully operational as the 'fourth pillar' following hotels, logistics, and overseas, significantly increasing the probability of achieving the 1.5 trillion yen AUM target
Summary
Kasumigaseki Capital's hospice business aims for the completed form of a 'development, operation, and REIT incorporation' cycle model, and the acquisition of operational know-how and facility scale through M&A is a rational growth strategy.
Among the four candidates, Amvis Holdings has the highest overall rating, but considering costs and risks, a three-stage approach of 'Nihon Hospice Holdings → CUC → Amvis Holdings' is the most realistic and steady path.
Against the backdrop of a structurally expanding market where the number of deaths will continue to rise toward 2040, whether Kasumigaseki Capital can establish itself as an 'integrated platform covering everything from development to end-of-life care' in the hospice market will be the key to its next growth phase.
Disclaimer
This article is for informational purposes only and is not intended as an investment solicitation.
All figures and estimates provided are based on publicly available information and projections, and do not guarantee future performance.
Actual investment and M&A decisions require due diligence by professionals and your own independent judgment.
